Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).
Cowley D, Sari RM, Handley A, Watts E, Bachtiar NS, At Thobari J, Satria CD, Bogdanovic-Sakran N, Nirwati H, Orsini F, Lee KJ, Kirkwood CD, Soenarto Y, Bines JE. Cowley D, et al. Among authors: bachtiar ns. Vaccine. 2019 Nov 20;37(49):7233-7239. doi: 10.1016/j.vaccine.2019.09.071. Epub 2019 Oct 10. Vaccine. 2019. PMID: 31607604 Free PMC article. Clinical Trial.
The immunogenicity, safety, and consistency of an Indonesia combined DTP-HB-Hib vaccine in expanded program on immunization schedule.
Rusmil K, Gunardi H, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, Satari HI, Risan NA, Prasetio D, Tarigan R, Garheni R, Milanti M, Hadinegoro SR, Tanuwidjaja S, Bachtiar NS, Sari RM. Rusmil K, et al. Among authors: bachtiar ns. BMC Pediatr. 2015 Dec 19;15:219. doi: 10.1186/s12887-015-0525-2. BMC Pediatr. 2015. PMID: 26686508 Free PMC article. Clinical Trial.
Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial.
At Thobari J, Damayanti W, Haposan JH, Nirwati H, Iskandar K, Samad, Fahmi J, Sari RM, Bachtiar NS, Watts E, Bines JE, Soenarto Y. At Thobari J, et al. Among authors: bachtiar ns. Vaccine. 2021 Jul 30;39(33):4651-4658. doi: 10.1016/j.vaccine.2021.06.071. Epub 2021 Jul 6. Vaccine. 2021. PMID: 34244006 Free article. Clinical Trial.
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, Bachtiar NS, Sukandar H, Megantara I, Murad C, Pangesti KNA, Setiawaty V, Sudigdoadi S, Hu Y, Gao Q, Kartasasmita CB. Fadlyana E, et al. Among authors: bachtiar ns. Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24. Vaccine. 2021. PMID: 34620531 Free PMC article. Clinical Trial.
DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.
Gunardi H, Rusmil K, Fadlyana E, Soedjatmiko, Dhamayanti M, Sekartini R, Tarigan R, Satari HI, Medise BE, Sari RM, Bachtiar NS, Kartasasmita CB, Hadinegoro SRS. Gunardi H, et al. Among authors: bachtiar ns. BMC Pediatr. 2018 May 28;18(1):177. doi: 10.1186/s12887-018-1143-6. BMC Pediatr. 2018. PMID: 29804542 Free PMC article. Clinical Trial.
Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, Satari HI, Hadinegoro SR, Yang JS, Excler JL, Sahastrabuddhe S, Puspita M, Sari RM, Bachtiar NS. Medise BE, et al. Among authors: bachtiar ns. PLoS One. 2019 Feb 13;14(2):e0211784. doi: 10.1371/journal.pone.0211784. eCollection 2019. PLoS One. 2019. PMID: 30759132 Free PMC article. Clinical Trial.
One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.
Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Wirahmadi A, Puspita M, Sari RM, Yang JS, Sil A, Sahastrabuddhe S, Bachtiar NS. Medise BE, et al. Among authors: bachtiar ns. Int J Infect Dis. 2020 Apr;93:102-107. doi: 10.1016/j.ijid.2020.01.045. Epub 2020 Jan 28. Int J Infect Dis. 2020. PMID: 32004693 Free article. Clinical Trial.
A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, Wirahmadi A, Puspita M, Sari RM, Yang JS, Sil A, Sahastrabuddhe S, Bachtiar NS. Medise BE, et al. Among authors: bachtiar ns. BMC Pediatr. 2020 Oct 15;20(1):480. doi: 10.1186/s12887-020-02375-4. BMC Pediatr. 2020. PMID: 33059607 Free PMC article. Clinical Trial.
34 results